Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACAD NASDAQ:AVXL NASDAQ:VCEL NASDAQ:XENE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACADACADIA Pharmaceuticals$20.65-5.0%$23.75$13.40▼$26.65$3.49B0.752.19 million shs1.64 million shsAVXLAnavex Life Sciences$8.92-1.2%$9.44$5.22▼$14.44$766.43M0.831.14 million shs604,494 shsVCELVericel$34.16+1.7%$33.74$29.24▼$63.00$1.72B1.39558,029 shs608,559 shsXENEXenon Pharmaceuticals$41.78-0.3%$38.04$26.74▼$46.00$3.23B1.14859,842 shs402,289 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACADACADIA Pharmaceuticals+6.78%+2.02%-11.88%-3.59%+45.81%AVXLAnavex Life Sciences+2.61%-8.32%-0.66%-18.35%+67.53%VCELVericel-3.03%-1.58%+6.91%-7.36%-19.93%XENEXenon Pharmaceuticals+3.28%+6.75%+16.42%+30.45%+2.92%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACADACADIA Pharmaceuticals$20.65-5.0%$23.75$13.40▼$26.65$3.49B0.752.19 million shs1.64 million shsAVXLAnavex Life Sciences$8.92-1.2%$9.44$5.22▼$14.44$766.43M0.831.14 million shs604,494 shsVCELVericel$34.16+1.7%$33.74$29.24▼$63.00$1.72B1.39558,029 shs608,559 shsXENEXenon Pharmaceuticals$41.78-0.3%$38.04$26.74▼$46.00$3.23B1.14859,842 shs402,289 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACADACADIA Pharmaceuticals+6.78%+2.02%-11.88%-3.59%+45.81%AVXLAnavex Life Sciences+2.61%-8.32%-0.66%-18.35%+67.53%VCELVericel-3.03%-1.58%+6.91%-7.36%-19.93%XENEXenon Pharmaceuticals+3.28%+6.75%+16.42%+30.45%+2.92%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACADACADIA Pharmaceuticals 2.65Moderate Buy$29.1241.03% UpsideAVXLAnavex Life Sciences 2.33Hold$44.00393.27% UpsideVCELVericel 2.71Moderate Buy$58.4070.98% UpsideXENEXenon Pharmaceuticals 2.92Moderate Buy$53.6728.45% UpsideCurrent Analyst Ratings BreakdownLatest AVXL, XENE, ACAD, and VCEL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/15/2025VCELVericelTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$46.00 ➝ $41.0010/14/2025ACADACADIA PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)10/14/2025VCELVericelZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy10/14/2025XENEXenon PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025AVXLAnavex Life SciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025VCELVericelWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)10/7/2025AVXLAnavex Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$42.0010/7/2025XENEXenon PharmaceuticalsBloom BurtonSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy10/7/2025XENEXenon PharmaceuticalsWilliam BlairSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform10/7/2025XENEXenon PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$55.0010/1/2025AVXLAnavex Life SciencesD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$46.00(Data available from 10/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACADACADIA Pharmaceuticals$1.02B3.42$0.71 per share28.89$4.40 per share4.69AVXLAnavex Life SciencesN/AN/AN/AN/A$1.42 per shareN/AVCELVericel$237.22M7.27$0.31 per share110.85$5.92 per share5.77XENEXenon Pharmaceuticals$7.50M429.53N/AN/A$9.90 per share4.22Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACADACADIA Pharmaceuticals$226.45M$1.3315.5427.177.1621.80%14.69%9.41%11/5/2025 (Estimated)AVXLAnavex Life Sciences-$43M-$0.57N/AN/AN/AN/A-45.67%-40.21%11/28/2025 (Estimated)VCELVericel$10.36M$0.12284.7777.63N/A2.85%2.47%1.69%11/6/2025 (Estimated)XENEXenon Pharmaceuticals-$234.33M-$3.55N/AN/AN/AN/A-38.50%-36.47%11/11/2025 (Estimated)Latest AVXL, XENE, ACAD, and VCEL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/11/2025Q3 2025XENEXenon Pharmaceuticals-$1.16N/AN/AN/AN/AN/A11/6/2025Q3 2025VCELVericel-$0.02N/AN/AN/A$64.57 millionN/A11/5/2025Q3 2025ACADACADIA Pharmaceuticals$0.14N/AN/AN/A$276.52 millionN/A8/12/2025Q3 2025AVXLAnavex Life Sciences-$0.13-$0.16-$0.03-$0.16N/AN/A8/11/2025Q2 2025XENEXenon Pharmaceuticals-$1.03-$1.07-$0.04-$1.07N/AN/A8/6/2025Q2 2025ACADACADIA Pharmaceuticals$0.14$0.16+$0.02$0.16$263.07 million$264.57 million7/31/2025Q2 2025VCELVericel-$0.04-$0.01+$0.03-$0.01$64.61 million$63.24 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACADACADIA PharmaceuticalsN/AN/AN/AN/AN/AAVXLAnavex Life SciencesN/AN/AN/AN/AN/AVCELVericelN/AN/AN/AN/AN/AXENEXenon PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACADACADIA PharmaceuticalsN/A2.912.83AVXLAnavex Life SciencesN/A8.938.93VCELVericelN/A4.974.56XENEXenon PharmaceuticalsN/A15.1415.14Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACADACADIA Pharmaceuticals96.71%AVXLAnavex Life Sciences31.55%VCELVericelN/AXENEXenon Pharmaceuticals95.45%Insider OwnershipCompanyInsider OwnershipACADACADIA Pharmaceuticals26.50%AVXLAnavex Life Sciences11.40%VCELVericel5.20%XENEXenon Pharmaceuticals4.07%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACADACADIA Pharmaceuticals510168.71 million124.00 millionOptionableAVXLAnavex Life Sciences4085.89 million76.10 millionOptionableVCELVericel30050.46 million47.84 millionOptionableXENEXenon Pharmaceuticals21077.11 million73.97 millionOptionableAVXL, XENE, ACAD, and VCEL HeadlinesRecent News About These CompaniesXenon Pharmaceuticals appoints Tucker Kelly as Chief Financial Officer2 hours ago | msn.comXenon Pharmaceuticals Appoints Tucker Kelly as CFO to Drive Commercialization EffortsOctober 16 at 9:31 AM | tipranks.comXenon Pharmaceuticals Inc. Appoints Tucker Kelly as Chief Financial Officer to Advance Commercialization of AzetukalnerOctober 16 at 8:51 AM | quiverquant.comQXenon Announces Appointment of Tucker Kelly as Chief Financial OfficerOctober 16 at 8:30 AM | globenewswire.comXenon (XENE) Receives a Buy from JefferiesOctober 16 at 4:15 AM | theglobeandmail.comXenon Pharmaceuticals (NASDAQ:XENE) Earns "Sell (D-)" Rating from Weiss RatingsOctober 16 at 2:07 AM | americanbankingnews.comInvestors Buy High Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE)October 16 at 2:31 AM | marketbeat.comAberdeen Group plc Boosts Position in Xenon Pharmaceuticals Inc. $XENEOctober 15 at 3:42 AM | marketbeat.comXenon Pharmaceuticals (NASDAQ:XENE) Given "Sell (D-)" Rating at Weiss RatingsOctober 14 at 12:48 PM | marketbeat.comXenon Pharmaceuticals (XENE): Exploring Valuation After Recent Share Price MomentumOctober 12, 2025 | finance.yahoo.comWhat is Bloom Burton's Forecast for XENE FY2025 Earnings?October 11, 2025 | americanbankingnews.comResearch Analysts Issue Forecasts for XENE FY2025 EarningsOctober 10, 2025 | marketbeat.comXenon Pharmaceuticals' (XENE) "Outperform" Rating Reiterated at William BlairOctober 10, 2025 | americanbankingnews.comBrokers Offer Predictions for XENE FY2026 EarningsOctober 8, 2025 | marketbeat.comBloom Burton Upgrades Xenon Pharmaceuticals (NASDAQ:XENE) to "Strong-Buy"October 8, 2025 | marketbeat.comChardan Capital Maintains Xenon Pharmaceuticals (XENE) Buy RecommendationOctober 7, 2025 | msn.comXenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 7, 2025 | financialpost.comFXenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 7, 2025 | globenewswire.comXenon Pharmaceuticals' (XENE) Outperform Rating Reiterated at William BlairOctober 7, 2025 | marketbeat.comXenon Pharmaceuticals (NASDAQ:XENE) Receives "Buy" Rating from Chardan CapitalOctober 7, 2025 | marketbeat.comXenon Pharmaceuticals Inc. (XENE) Nav1.7 And Kv7 Programs Investor Webinar TranscriptOctober 6, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAVXL, XENE, ACAD, and VCEL Company DescriptionsACADIA Pharmaceuticals NASDAQ:ACAD$20.65 -1.09 (-5.03%) As of 03:22 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.Anavex Life Sciences NASDAQ:AVXL$8.92 -0.11 (-1.22%) As of 03:22 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.Vericel NASDAQ:VCEL$34.16 +0.57 (+1.69%) As of 03:21 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.Xenon Pharmaceuticals NASDAQ:XENE$41.78 -0.12 (-0.29%) As of 03:22 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Qualcomm: What Last Friday’s Drop Says About Its Q4 Prospects An AI Play Hiding in Plain Sight: A Look at Johnson Controls Walmart's AI Play: OpenAI Deal Forges a New Path to Profitability AppLovin Drops 14%: Should Investors Worry About SEC Probe? Advanced Micro Devices Eyes $300 as AI Demand Surges From Bulldozers to Big Data: Caterpillar’s Bull Case Gets a Lift Why Analysts Are Upgrading Ratings After Klarna's IPO 3 Healthcare Companies Insiders Are Buying Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
